Diplomat Pharmacy (DPLO) Lowered to Hold at Lake Street Capital

Lake Street Capital cut shares of Diplomat Pharmacy (NYSE:DPLO) from a buy rating to a hold rating in a research note released on Tuesday, MarketBeat Ratings reports. Lake Street Capital currently has $15.00 price objective on the stock, down from their prior price objective of $30.00.

Several other brokerages have also issued reports on DPLO. ValuEngine lowered Diplomat Pharmacy from a hold rating to a sell rating in a research note on Wednesday, September 12th. Zacks Investment Research lowered Diplomat Pharmacy from a hold rating to a strong sell rating in a research note on Thursday, January 3rd. Morgan Stanley decreased their price objective on Diplomat Pharmacy from $20.00 to $18.00 and set an equal weight rating on the stock in a research note on Monday, December 3rd. Robert W. Baird upgraded Diplomat Pharmacy from an underperform rating to a neutral rating and boosted their price objective for the company from $10.00 to $15.00 in a research note on Friday, December 7th. Finally, Wells Fargo & Co decreased their price objective on Diplomat Pharmacy from $23.00 to $16.00 and set a market perform rating on the stock in a research note on Thursday, November 8th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $22.70.

Diplomat Pharmacy stock traded down $0.06 during mid-day trading on Tuesday, reaching $13.14. 15,370 shares of the company’s stock were exchanged, compared to its average volume of 868,337. The firm has a market capitalization of $997.22 million, a P/E ratio of 15.64 and a beta of 0.97. Diplomat Pharmacy has a one year low of $12.30 and a one year high of $28.74. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.21). The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 earnings per share. Analysts predict that Diplomat Pharmacy will post 0.8 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Swiss National Bank grew its position in Diplomat Pharmacy by 8.2% during the second quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $2,306,000 after buying an additional 6,800 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Diplomat Pharmacy by 7.8% in the 3rd quarter. Wells Fargo & Company MN now owns 95,621 shares of the company’s stock worth $1,856,000 after purchasing an additional 6,898 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Diplomat Pharmacy in the 3rd quarter worth about $696,000. SG Americas Securities LLC boosted its holdings in shares of Diplomat Pharmacy by 147.5% in the 2nd quarter. SG Americas Securities LLC now owns 12,820 shares of the company’s stock worth $328,000 after purchasing an additional 7,640 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in shares of Diplomat Pharmacy by 15.3% in the 3rd quarter. Louisiana State Employees Retirement System now owns 24,900 shares of the company’s stock worth $483,000 after purchasing an additional 3,300 shares in the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply